



Chemotherapy-Induced Nausea and Vomiting



A single-dose regimen can provide economic and the potential for side effects.

Gralla RJ, et al. ASCO Rec for the use of antiemetics clinical practice guideline 1999; 17(9):2971-2994.

Introduction • e

Product Information

ANZEMET® Formulary Kit

Patient Assistance and Reimbursement Programs

Managed Care

Professional Support

**Sign Up for
More Information**

Auzemef.com Home


**For help and
inspiration in dealing
with nausea and
vomiting, tell your
patients to**

Go to



IV Optimal control with a single dose

24-HOUR EMESIS PREVENTION WITH VARYING DOSES OF CISPLATIN*



A single dose of ANZEMET® prevents nausea and vomiting in the majority of patients receiving high-dose cisplatin.^{1,2,3,4}

*Results from two separate, multi-center, double-blind, randomized studies. ANZEMET® dose was 1.8 mg/kg. Complete response defined as no emetic episodes and no rescue medication for 24 hours after dosing.

Zofran® is a registered trademark of Glaxo Group Limited.
Kytril® is a registered trademark of Hoffman-La Roche Inc.

ANZEMET® Injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including high-dose cisplatin.

The most common adverse events (>4%) in chemotherapy patients are headache, fatigue, diarrhea, and bradycardia.

http://www.anzemet.com/c_intro.html

01/05/2004

headache, diarrhea, and fever (injection).

ANZEMET® can cause ECG interval changes; it should be administered with caution in patients who have or may de
prolongation of cardiac conduction intervals.

Please see full prescribing information for ANZEMET® Injection and ANZEMET® Tablets.

© 2003 Aventis Pharmaceuticals Inc. This site is intended for use by U.S. residents only.
[Aventis Pharmaceuticals U.S. Home Page](#) [Terms of Use](#) [Privacy Policy](#)

ANZ-WS-8581-1